Supreme Court Justice Samuel A. Alito Jr. extended a temporary pause on a 5th Circuit ruling that would tighten access to the abortion medication mifepristone. The stay, effective until 5 p.m. May 14, keeps the drug available nationwide by mail, preserving telemedicine prescriptions that many patients now rely on in states with restrictive laws.

The 5th Circuit’s decision followed Louisiana officials’ lawsuit against the FDA, arguing that removing the in‑person dispensing requirement undermined the state’s near‑total abortion ban. Manufacturers Danco Laboratories and GenBioPro petitioned the Court, warning that a nationwide rollback could trigger uneven state‑by‑state drug regulation for pharmaceutical firms.

Industry observers note that mifepristone accounts for nearly two‑thirds of U.S. abortions, and the pause keeps a vital revenue stream flowing to the two manufacturers. A permanent restriction could ripple through the pharmaceutical supply chain, affecting pricing and availability of early‑stage abortion therapies for patients nationwide.

Until the Supreme Court issues a final ruling, the status quo remains, ensuring that patients in states with strict abortion bans can still access mifepristone by mail. This interim measure protects a key component of reproductive health care and maintains the market for two leading manufacturers.